Evaluation of chemokines as a biomarker for assessing the severity of canine atopic dermatitis
The University of Florida College of Veterinary Medicine is currently recruiting dogs diagnosed with atopic dermatitis for a clinical research study to find a biomarker for assessing severity of canine atopic dermatitis.
- Inclusion Criteria: Dogs between 1-10 years of age and weight ≥10kg will be enrolled in this study. At the time of enrollment, healthy dogs will have no history of skin disease and will be clinically healthy. Atopic dogs will have a diagnosis of atopic dermatitis (AD) by a board certified dermatologist. Each dog must be on strict flea prevention monthly.
- Procedures: Participation includes 1 visit for collecting blood and a skin biopsy sample and 1 recheck visit at 1-2 weeks for suture removal from sites where skin biopsy was collected. Complete dermatological examinations will be performed at the first visit.
- Costs: The study will cover the costs associated with each visit for this trial.
- Contact: Please contact the Small Animal Hospital at (352) 392-2235 for more information, or email VM-ClinicalStudies@ufl.edu . Drs. Chong and Santoro are the Principal Investigators.
Atopic dermatitis (AD) is a very common allergic skin disease in dogs and people. The causes of allergies are not well understood, and may involve multiple factors. Changes in production small molecules produced by the immune system called chemokines may be associated with AD. Limited information is available for these chemokines in dogs, thus the purpose of this study is to evaluate the levels of these chemokines in various parts of blood, and skin of dogs with AD. In addition, we want to determine if levels of these chemokines may be related to the severity of AD. The long-term goal of this study is to find a potential tool for monitoring and treating AD in dogs and humans.